The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
RavandiF.EsteyE.JonesD.Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol.2009; 27(4): 504–510.
2.
EsteyE.Garcia-ManeroG.FerrajoliA.Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood.2006; 107(9): 3469–3473.
3.
Lo-CocoF.AvvisatiG.VignettiM.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med.2013; 369(2): 111–121.
4.
AuW.Y.KumanaC.R.LeeH.K.Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: A 10-year follow-up study. Blood.2011; 118(25): 6535–6543.
5.
BurnettA.K.RussellN.H.HillsR.K.Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial. Lancet Oncol.2015; 16(13): 1295–1305.
6.
DaiC.W.ZhangG.S.ShenJ.K.Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol.2009; 121(1): 1–8.
7.
ShenZ.X.ShiZ.Z.FangJAll-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA.2004; 101(15): 5328–5335.
8.
ZhuH.H.HuangX.J.Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med.2014; 371(23): 2239–2241.
9.
RaffouxE.RousselotP.PouponJ.Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol.2003; 21(12): 2326–2334.
10.
ZhuH.H.WuD.P.JinJ.Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: A multicenter randomized controlled trial. J Clin Oncol.2013; 31(33): 4215–4221.
MarounJ.A.AnthonyL.B.BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
18.
BensonA.B.AjaniJ.A.CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol2004; 22(14): 2918–2926.
